Pregabalin for peripheral neuropathic pain
Hadj Tahar A
Record ID 32005000216
English, French
Authors' objectives:
The aim of this report is to review the available information on the use of pregabalin (Trade Mark: Lyrica), an anticonvulsant drug, in the treatment of adults with peripheral neuropathic pain (NeP).
Authors' recommendations:
The costs associated with pregabalin treatment may not compare favourably with that of generic gabapentin. However, gabapentin is not approved for the treatment of NeP by Health Canada. While pregabalin appears to be an effective treatment for NeP, there is no evidence that it offers advantages compared with other treatments being used in Canada. The long-term effects of treating NeP with pregabalin are largely unknown, because long-term RCTs are unavailable. Comparative cost and consequence data from head-to-head trials with recommended therapies are needed to define pregabalin s place in NeP therapy.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anticonvulsants
- Costs and Cost Analysis
- Pain
- Peripheral Nervous System Diseases
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.